Global Osteoporosis Treatment Market, by Drugs Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, and Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, and Rank Ligand (RANKL) Inhibitor), by Route of Administration (Oral, Injectable, and Others), by Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 11.8 Bn in 2017, and is projected to exhibit a CAGR of 3.8% over the forecast period (2018 – 2026). According to ’ analysis, global osteoporosis treatment market is expected to show significant growth over the forecast period, owing to frequent launches and robust pipeline of novel products for treatment of osteoporosis. For instance, in May, 2018, Pfenex Inc. announced top-line results from its PF708-301 study, which show comparable overall profiles between PF708 and Forteo. PF708 is a teriparatide drug candidate that is under development as a therapeutic equivalent to Forteo— a drug of Eli Lilly and Company— indicated for the treatment of osteoporosis patients at a high risk of fracture. In third quarter of 2018, Pfenex Inc. expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its PF708. In 2017, Radius Health, Inc. received US Food and Drug Administration approval for its YMLOS (abaloparatide) injection. YMLOS (abaloparatide) injection is a bone building agent indicated for the treatment of postmenopausal women with osteoporosis. In 2016, Asahi Kasei Pharma Corporation and Dong-A ST Co. Ltd., launched – drug Teribone (generic name: teriparatide acetate) in Korea, which is a subcutaneous injection indicated for the treatment of osteoporosis.
Browse 32 Market Data Tables and 30 Figures spread through 165 Pages and in-depth TOC on Osteoporosis Treatment Market, By Drugs Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, and Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, and Rank Ligand (RANKL) Inhibitor), by Route of Administration (Oral, Injectable, and Others), by Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the Osteoporosis Treatment Market, click the link below:
Increasing investments by key players in the market for development of novel osteoporosis treatment drug is expected to fuel global osteoporosis treatment market growth. For instance, in May 2018, Pfenex Inc. raised around US$ 39.4 million from public offering for the development and launch of its novel osteoporosis drug PF708, which is under clinical trial. Furthermore, key players in the market are involved in strategic sale and marketing partnership with other companies to expand its product presence in various key regions. For instance, in 2014, Asahi Kasei Pharma entered into strategic partnership with South Korea-based, Dong-A ST Co. Ltd. According to the partnership, Asahi Kasei Pharma granted exclusive development and sale rights of Teribone osteoporosis drug to Dong-A ST Co. Ltd. in South Korea. Such strategic partnership for expansion of products in key regions is expected to propel osteoporosis treatment market growth over the forecast period.
Key Takeaways of the Osteoporosis Treatment Market:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.